Barclays
AARD icon

Barclays’s Aardvark Therapeutics AARD Stock Holding History

Barclays’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$136K Buy
25,792
+23,533
+1,042% +$144K ﹤0.01% 4179
2026
Q2 		$13K Sell
2,259
-1,362
-38% -$6.36K ﹤0.01% 4666
2026
Q1 		$13.7K Sell
3,621
-16,895
-82% -$175K ﹤0.01% 4652
2025
Q4 		$269K Sell
20,516
-19,410
-49% -$242K ﹤0.01% 4170
2025
Q3 		$531K Sell
39,926
-10,632
-21% -$120K ﹤0.01% 3771
2025
Q2 		$684K Buy
+50,558
New +$521K ﹤0.01% 3577

Other funds holding AARD

Laurion Capital Management
Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57.1B AUM 43.46% 1-Year Est. Return
Stone House Investment Management
Stone House Investment Management Tunkhannock, Pennsylvania $768M AUM 12.07% 1-Year Est. Return
Allworth Financial
Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

Barclays's AARD Position: Q3 2026 in Review

Barclays increased its Aardvark Therapeutics (AARD) stake by 1,042% in Q3 2026, buying an estimated $144K and bringing the position to 25,792 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #4179.

Barclays first reported a position in AARD in Q2 2025 and has held it in 6 quarters since. The position peaked at $684K in Q2 2025. 23 funds tracked by Wall St. Rank hold AARD as of Q3 2026.

  • Barclays held 25,792 shares of Aardvark Therapeutics worth $136K as of Q3 2026.
  • Barclays bought 23,533 Aardvark Therapeutics shares in Q3 2026, an estimated $144K.
  • Aardvark Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4179 holding.
  • Barclays first reported a position in Aardvark Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Barclays's Aardvark Therapeutics position peaked at $684K in Q2 2025.
  • 23 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.